Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01976390 · ClinicalTrials.gov registry record · NA
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01976390 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 60 participants.
The verdict
NCT01976390, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
Interventions
- DRUG Sirolimus
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-10-01 |
| Est. Completion | 2019-08-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01976390
The ClinicalTrials.gov registry entry for NCT01976390 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT01976390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01976390 about?
NCT01976390 is a clinical study titled "Comparing Everolimus and Sirolimus in Renal Transplant Recipients". This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
What is the current status of trial NCT01976390?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2013-10-01. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT01976390?
The interventions under investigation include: Sirolimus (DRUG), Everolimus (DRUG).
Who is sponsoring clinical trial NCT01976390?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.